• Home
  • NEW DAY MEDICINE
  • 5 (67) 2024
  • 33 -5 (67) 2024 - Abdulatipova F.A., Kurbanov B.B. - FEATURES OF SOMATIC AND GYNECOLOGICAL ANAMNESIS OF WOMEN WITH ENDOMETRIAL HYPERPLASIA

33 -5 (67) 2024 - Abdulatipova F.A., Kurbanov B.B. - FEATURES OF SOMATIC AND GYNECOLOGICAL ANAMNESIS OF WOMEN WITH ENDOMETRIAL HYPERPLASIA

FEATURES OF SOMATIC AND GYNECOLOGICAL ANAMNESIS OF WOMEN WITH ENDOMETRIAL HYPERPLASIA

Abdulatipova F.A. - Tashkent Pediatric Medical Institute

Kurbanov B.B. - Tashkent Pediatric Medical Institute

Kurbanov D.D. - Tashkent Pediatric Medical Institute

Resume

The reasons for the development of endometrial hyperplastic processes are multifactorial, controversial and not fully understood. There are no clear mechanisms explaining the etiology of the disease. The purpose of this study was to study the main clinical, laboratory and anamnestic criteria of women with endometrial hyperplastic conditions.

Keywords: hyperplasia, uterus, endometrium.

First page

193

Last page

196

For citation: Abdulatipova F.A., Kurbanov B.B., Kurbanov D.D.- FEATURES OF SOMATIC AND GYNECOLOGICAL ANAMNESIS OF WOMEN WITH ENDOMETRIAL HYPERPLASIA//New Day in Medicine 5(67)2024 193-196 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Jabbour HN, Kelly RW, Fraser HM, Critchley HO. Endocrine regulation of menstruation. Endocr Rev. 2006; 17–46.
  2. Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update. 2007; 567–580.
  3. Daud S, Jalil SS, Griffin M, Ewies AA. Endometrial hyperplasia - the dilemma of management remains: a retrospective observational study of 280 women. Eur J Obstet Gynecol Reprod Biol. 2011; 172–175.
  4. Ozdegirmenci O, Kayikcioglu F, Bozkurt U, Akgul M.A, Haberal A. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Gynecol Obstet Invest. 2011; 10–14.
  5. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013; 1533–1541.
  6. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, et al. Enhanced estrogen-induced proliferation in obese rat endometrium. Am //J Obstet Gynecol. 2009; 200:186.e1–186.e8.
  7. Reed S.D, Newton K.M, Garcia R.L, Allison K.H, Voigt L.F, Jordan C.D, et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol. 2010; 365–373.
  8. Bese T, Vural A, Ozturk M, Dagistanli F, Demirkiran F, Tuncdemir M, et al. The effect of long-term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia. Int J Gynecol Cancer. 2006; 809–813.
  9. Haimovich S, Checa MA, Mancebo G, Fusté P, Carreras R. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device. /Menopause. 2008; 1002–1004.
  10. Kim MK, Seong SJ. Conservative treatment for atypical endometrial hyperplasia: what is the most effective therapeutic method? J Gynecol Oncol. 2014; 164–165.
  11. Cormio A, Guerra F, Cormio G, Pesce V, Fracasso F, Loizzi V, et al. Mitochondrial DNA content and mass increase in progression from normal to hyperplastic to cancer endometrium. BMC Res Notes. 2012; 5:279.
  12. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am //J Surg Pathol. 2007; 988–998.
  13. Trimble C.L, Method M, Leitao M, Lu K, Ioffe O, Hampton M, et al. Management of endometrial precancers. Obstet Gynecol. 2012; 1160–1175.
  14. Oza A.M, Eisenhauer E.A, Elit L, Cutz J.C, Sakurada A, Tsao MS, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008; 26:4319–4325.
  15. Bruchim I, Sarfstein R, Werner H. The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches. Front Endocrinol (Lausanne). 2014; 5:76.
  16. Emarh M. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study. Arch Gynecol Obstet. 2015.
  17. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. //J Clin Oncol. 2007; 2798–2803.
  18. Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric. 2013; 16:490–498.
  19. Upson K, Allison KH, Reed SD, Jordan CD, Newton KM, Swisher EM, et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am //J Obstet Gynecol. 2012; 207:36.e1–36.e8.
  20. Chen X, Zhang Z, Feng Y, Fadare O, Wang J, Ai Z, et al. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Mod Pathol. 2009; 22:699–708.

    file

    download